First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic CancerSarah P. Blagden, Udai Banerji, Karen E. Swales et al.|Clinical Cancer Research|2014Cited by 47
A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors.Aurelius Omlin, Sarah P. Blagden, James Spicer et al.|Journal of Clinical Oncology|2012Cited by 5
Data from First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic CancerSarah P. Blagden, Udai Banerji, Aurelius Olmin et al.|Unknown|2023Cited by 0
Data from First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic CancerSarah P. Blagden, Udai Banerji, Aurelius Olmin et al.|Unknown|2023Cited by 0